This online seminar will provide an overview of the use of liquid biopsies for cancer recurrence monitoring with a particular focus on colorectal cancer.
Analysis of circulating tumor DNA (ctDNA) has the potential to improve detection and monitoring of cancers in order to significantly impact patient outcomes. This is especially important for cancers with a high rate of recurrence, such as colorectal cancer, where between 30 percent and 40 percent of cases recur. However, the only currently available monitoring blood test misses 74 percent of resectable recurrences.
In this webinar, Dr. Lawrence LaPointe, CEO of Clinical Genomics, will discuss how his team is working with Qiagen to develop a ctDNA test for colorectal cancer recurrence monitoring.
Additionally, Dr. Martin Horlitz will briefly share how Qiagen's ctDNA extraction chemistries are compliant with ISO and IVD quality guidelines.
CONGRATULATIONS, your MEMBS membership profile is almost done, by clicking submit you will be eligible to join and browse any of MEMBS websites or activities
Please enter your email
One time is better than every time!
By providing your email, name, and organization this time, you will be booking your membership account with lifetime validity, and you will not be compelled to fill them again each time you make a registration or a submission through any activity or website of MEMBS.
MEMBS will not ask you to log-in again as long as you are using the same device and the same browser.
Not only this! You will be awarded each time you make any registration or submission; you will also be collecting certificates of participation, and you can easily meet others –from the resion and abroad- who share the same area of interest with you.